Some of the companies operatingin the GastricCancer Therapeutics Market in the current scenario are Pfizer, Eli Lilly,GlaxoSmithKline plc, Kuhnil Pharmaceutical/Daiichi Sankyo, BMS, Merck KGaA,AstraZeneca, Otsuka Holdings Co. Ltd., Sanofi, and F. Hoffmann-La Roche Ltd.Some of the other companies operating in the market are OnoPharmaceutical/Bristol-Myers Squibb, Jiangsu HengRui Medicine, GileadBioscience, Celgene/Taiho, Boston Biomedical, and Merck.
Gastric cancer, also known asstomach cancer, is a type of cancer that develops within the inside layer ofthe stomach. Symptoms may include upper abdominal pain, yellowing of the skin,heartburn, sudden weight loss, blood in the stool, loss of appetite, andnausea, among others. This type of cancer may multiply to unaffected parts ofthe body mainly to the lungs, liver, the lining of the abdomen, lymph nodes,and bones. The key cause of gastric cancer is contagion by Helicobacter pylori.This accounts for around 60% of the gastric cancer cases. Some types of H.pylori comprise larger risks than the others. Some of the other causes includesmoking and eating pickled vegetables. Around 1 in 10 cases of gastric cancerare inherited and 1% to 3% of the cases are due to hereditary syndromes such ashereditary gastric cancer. Most cases of gastric cancers are gastriccarcinomas.
According to World Cancer ResearchFund International, 952,000 new cases of gastric cancer were diagnosed in 2012.Gastric cancer was the fifth-most common type of cancer in the world. Thisepidemic has forced researchers, doctors, and governments to adopt varioustherapeutic treatments related to gastric cancer. An increase in investment bythe companies and regulations by the government encouraging research on thesame has provided significant momentum to the growth of the gastric cancertherapeutics market. This trend is likely to persist throughout the forecastperiod, since the number of cases of gastric cancer around the globe is risingat an alarming rate.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/194
According to National Cancer Institute,there were a projected 79,843 individuals with stomach cancer in the U.S.alone, in 2013. According to the same report, gastric cancer represented awhopping 1.6% of the new cancer cases reported in the U.S. According to theNational Cancer Institute, an estimated 26,370 new cases of the disease werereported, leading to 10,730 deaths in the U.S. in 2016. Rising incidence ofstomach cancer in the U.S., positions it as a high growth market for gastriccancer therapeutics.
Increasing prevalence of thedisease in the Asia to drive growth of overall gastric cancer therapeuticsmarket
Survival rate for stomach canceris greatly dependent upon the stage or phase of the disease during diagnosis.The earlier the stage of the disease progression, the higher is the survivalrate. In Asia Pacific, the majority of the cases are detected at the laterstage of the disease and predominantly among the geriatric population. Growthof the geriatric population in the region is leading to a proportional increasein occurrence of gastric cancer. This factor, along with growing healthawareness leading to a rise in demand for early detection would fuel growth ofthe gastric cancer therapeutics industry over the forecast period.
Presently, the products availablein the market constitutes of an extensive variety of treatment alternativessuch as angiogenesis inhibitors, new chemotherapies and HER2-targeted therapy.However, demand for therapeutics that can take care of HER2-negative stomachcancer patients is high. Nevertheless, the gastric cancer market isexperiencing a gradual change from generic treatment regimen to targetedtherapies. This will further enhance the growth of the global gastric cancertherapeutics market.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/gastric-cancer-therapeutics-market-194
Key Developments
Key players in the market arefocused on launching new products to expand their product portfolio. Forinstance, in April 2019, F. Hoffmann-La Roche AG launched VENTANA HER2 Dual ISHDNA Probe Cocktail assay for the detection of the HER2 biomarker in breast andgastric cancer.
Major market players are focusedon adopting collaboration strategies to develop novel therapies for gastriccancer. For instance, in February 2019, GlaxoSmithKline plc. and Merck KGaAentered into a global strategic alliance to jointly develop and commercializeM7824, an investigational bifunctional fusion protein immunotherapy underclinical development stage, for the treatment of humanpapillomavirus-associated cancers, biliary tract cancer (BTC), and gastriccancer.
Key market players are alsofocused on gaining regulatory approvals to expand their product portfolio. Froinstance, in August 2019, Taiho Pharmaceutical Co., Ltd. obtained additionalindication of unresectable advanced or recurrent gastric cancer that hasprogressed after chemotherapy for its anticancer agent LONSURF, an oralanticancer drug that uses the combination of trifluridine (antineoplasticnucleoside analogue) and tipiracil (a thymidine phosphorylase inhibitor), fromthe Japanese Ministry of Health, Labor and Welfare.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/194
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consulting services,and competitive analysis through various recommendations related to emergingmarket trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
